Pharmaceutical composition and kit for treating RB1-positive cancer

Combining CDK4 and 6 inhibitors with NF-κB or AKT inhibitors addresses the inefficacy of single-agent CDK inhibitors for RB1-positive cancers, achieving effective cell death and tumor reduction in RB1-positive cancers like hepatocellular carcinoma, breast cancer, and lung cancer.

JP7579564B2Active Publication Date: 2024-11-08KANAZAWA UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2020180429
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-10-28
Publication Date
2024-11-08
Estimated Expiration
2040-10-28

AI Technical Summary

Technical Problem

Single-agent administration of cyclin-dependent kinase (CDK) 4 and 6 inhibitors is not optimal for treating RB1-positive cancer, as indicated by in vitro and in vivo studies.

Method used

A combination of CDK4 and 6 inhibitors with either an NF-κB signaling pathway inhibitor or an AKT inhibitor is used, including specific compounds like palbociclib, ribociclib, and Bay11-7082, to target RB1-positive cancers such as hepatocellular carcinoma, breast cancer, and lung cancer.

Benefits of technology

The combination effectively induces cell cycle arrest, senescence, and apoptosis in RB1-positive cancer cells, demonstrating significant cytotoxicity and tumor suppression in both in vitro and in vivo models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579564000001
    Figure 0007579564000001
  • Figure 0007579564000002
    Figure 0007579564000002
  • Figure 0007579564000003
    Figure 0007579564000003
Patent Text Reader

Abstract

To provide a technique for effectively treating RB Transcriptional Corepressor 1 (RB1) positive cancer.SOLUTION: A pharmaceutical composition for treating RB1 positive cancer contains a combination of a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor as active ingredients. A method and a kit for testing the effectiveness of administering the pharmaceutical composition to a cancer patient include: a process of inspecting whether or not a cancer cell derived from a cancer patient is RB1-positive, in which the cancer cell indicating RB1-positive shows that administration of the pharmaceutical composition is effective for treating the cancer patient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition and a kit for treating RB1-positive cancer. More specifically, the present invention relates to a pharmaceutical composition for treating RB1-positive cancer, a kit for treating RB1-positive cancer, a method for testing the effectiveness of administering a medicine to a cancer patient, and a kit for testing the effectiveness of administering a medicine to a cancer patient. [Background technology]

[0002] Currently, the efficacy of single-agent administration of cyclin-dependent kinase (CDK) 4 and 6 inhibitors against various types of cancer including hepatocellular carcinoma is being investigated in phase II clinical trials (Non-Patent Document 1). [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Schettini F., et al., CDK 4 / 6 Inhibitors as Single Agent in Advanced Solid Tumors, Front Oncol., 8, 608, 2018. Summary of the Invention [Problem to be solved by the invention]

[0004] However, the inventors have demonstrated that single-agent administration of CDK4 and 6 inhibitors to cancer cell lines is effective but not optimal in in vitro and in vivo studies. The present invention aims to provide a technology for effectively treating RB1-positive cancer. [Means for solving the problem]

[0005] The present invention includes the following aspects. [1] A pharmaceutical composition for treating RB Transcriptional Corepressor 1 (RB1)-positive cancer, comprising as active ingredients a combination of a cyclin-dependent kinase (CDK) 4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor. [2] The pharmaceutical composition according to [1], wherein the CDK4 and 6 inhibitor is palbociclib (CAS number: 571190-30-2), ribociclib (CAS number: 1211441-98-3), abemaciclib (CAS number: 1231929-97-7), trilaciclib (CAS number: 1374743-00-6) or relociclib (CAS number: 1628256-23-4). [3] The pharmaceutical composition according to [1] or [2], comprising a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor as active ingredients, wherein the NF-κB signaling pathway inhibitor is an IKKβ inhibitor or an NF-κB inhibitor. [4] The NF-κB signaling pathway inhibitor is an IKKβ inhibitor, and the IKKβ inhibitor is selected from the group consisting of Bay11-7082 (CAS number: 19542-67-7), IMD-0354 (CAS number: 978-62-1), IMD-1041 (CAS number: 1073666-73-5), IMD-2560, and TPCA1 (CAS number: 507475-1 7-4), BOT-64 (CAS number: 113760-29-5), BMS345541 (CAS number: 445430-58-0), SC-514 (CAS number: 354812-17-2), IKK-16 (CAS number: 1186195-62-9), eltiprotafib (CAS number: 251303-04-5) and Bay65-1942 (HCl salt) (CAS number: 600734-06-3). The pharmaceutical composition according to [3]. [5] The NF-κB signaling pathway inhibitor is an NF-κB inhibitor, and the NF-κB inhibitor is selected from the group consisting of QNZ (CAS number: 545380-34-5), JSH-23 (CAS number: 749886-87-1), GYY4137 (CAS number: 106740-09-4), p-XSC (CAS number: 85539-83-9), CV3988 (CAS number: 85703-73-7), prostaglandin E2 (CAS number: 363-24-6), LY294002 (CAS number: 154447-36-6), Wortmannin (CAS number: 19545-26-7), mesalamine (CAS number: 89-57-6), rolipram (CAS number: 85416-75-7), gallic acid (CAS number: 149-91-7), anacardic acid (CAS number: 16611-84-0), MG-115 (CAS number: 133407-86-0), MG-132 (CAS number: 133407-82-6), lactacystin (CAS number: 133343-34-7), epoxomicin (CAS number: 134381-21-8), parthenolide (CAS number: No.: 20554-84-1), carfilzomib (CAS No.: 868540-17-4), bortezomib (CAS No.: 179324-69-7), MLN-4924 (CAS No.: 905579-51-3), delanzomib (CAS No.: 847499-27-8), ixazomib (CAS No.: 1239908-20-3), marizomib (CAS No.: 437742-34-2) and oprozomib (CAS No.: 935888-69-0). [3] The pharmaceutical composition according to claim 3. [6] The pharmaceutical composition according to [1] or [2], comprising a combination of a CDK4 and 6 inhibitor and an AKT inhibitor as active ingredients, wherein the AKT inhibitor is selected from the group consisting of Akt Inhibitor X (CAS number: 925681-41-0), ipatasertib (CAS number: 1001264-89-6), capivasertib (CAS number: 1143532-39-1), mirasertib (CAS number: 1313881-70-7), afuresertib (CAS number: 1047644-62-1), uprosertib (CAS number: 1047634-65-0), triciribine phosphate (CAS number: 61966-08-3) and MK2206 (CAS number: 1032350-13-2). [7] The pharmaceutical composition according to any one of [1] to [6], wherein the RB1-positive cancer is hepatocellular carcinoma, breast cancer, lung cancer or colon cancer. [8] A kit for treating RB1-positive cancer, comprising a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor. [9] A method for testing the effectiveness of administering a combination of a CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor to a cancer patient, the method comprising the step of examining whether cancer cells derived from a cancer patient are RB1 positive, wherein the RB1-positive cancer cells indicate that administration of the combination is effective in treating the cancer patient.

[10] A kit for testing the effectiveness of administration of a combination of a CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor to a cancer patient, comprising a primer set for amplifying genomic DNA of the RB1 gene, a probe for genomic DNA of the RB1 gene, a primer set for amplifying cDNA of the RB1 gene, a probe for mRNA of the RB1 gene, or a specific binding substance for RB1 protein, which is used to test whether cancer cells derived from a cancer patient are RB1 positive, and the fact that the cancer cells are RB1 positive indicates that administration of the combination of the CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor is effective in treating the cancer patient. Effect of the Invention

[0006] According to the present invention, a technique for effectively treating RB1-positive cancer can be provided. [Brief description of the drawings]

[0007] [Figure 1] FIG. 1 is a schematic diagram illustrating the action of CDK4 and 6 inhibitors on RB1. [Diagram 2] (a) is a schematic diagram explaining the procedure for generating QKO mice, and (b) is a representative photograph of a tumor formed in the liver of a QKO mouse. [Diagram 3] Graph (a) shows the results of flow cytometry in Experimental Example 2. Graph (b) is a graph prepared based on the results of (a). [Figure 4] 1 is a graph showing the results of screening in Experimental Example 3. [Diagram 5] 1 is a graph showing cell viability in a study using Bay11-7082 in Experimental Example 4. [Figure 6] 1 is a graph prepared based on the results of flow cytometry in a study using Bay11-7082 in Experimental Example 4. [Figure 7] 1 is a graph prepared based on the results of flow cytometry in a study using IMD-0354 in Experimental Example 4. [Figure 8] 13 is a graph prepared based on the results of flow cytometry in a study using shRNA against IKKβ in Experimental Example 4. [Figure 9] 1 is a graph prepared based on the results of flow cytometry in a study using primary hepatocellular carcinoma cells (QKO PHCC) in Experimental Example 4. [Figure 10] 1 is a graph prepared based on the results of flow cytometry in an investigation using Huh7 cells in Experimental Example 5. [Figure 11] 1 is a graph prepared based on the results of flow cytometry in a study using Li-7 cells in Experimental Example 5. [Figure 12]1 is a graph prepared based on the results of flow cytometry in an investigation using H1975 cells in Experimental Example 5. [Figure 13] 1 is a graph prepared based on the results of flow cytometry in a study using HCC1143 cells in Experimental Example 5. [Figure 14] 1 is a graph prepared based on the results of flow cytometry in an investigation using T47D cells in Experimental Example 5. [Figure 15] 1 is a graph prepared based on the results of flow cytometry in a study using HCT-116 cells in Experimental Example 5. [Figure 16] This is a graph created based on the results of flow cytometry in a study using DLD-1 cells in Experimental Example 5. [Figure 17] 1 is a graph prepared based on the results of flow cytometry in a study of the combined use of ribociclib and Bay11-7082 in Experimental Example 5. [Figure 18] 13 is a graph prepared based on the results of flow cytometry in the study of combined use of abemaciclib and Bay11-7082 in Experimental Example 5. [Figure 19] 1 is a graph prepared based on the results of flow cytometry in Experimental Example 6. [Figure 20] 1 is a graph prepared based on the results of flow cytometry in a study using HepG2 cells in Experimental Example 7. [Figure 21] 1 is a graph prepared based on the results of flow cytometry in an investigation using SW480 cells in Experimental Example 7. [Figure 22] 1 is a graph prepared based on the results of flow cytometry in a study using HCT-116 cells in Experimental Example 7. [Figure 23] This is a graph created based on the results of flow cytometry in a study using DLD-1 cells in Experimental Example 7. [Figure 24]1 is a graph prepared based on the results of flow cytometry in a study using A549 cells in Experimental Example 7. [Diagram 25] 1 is a graph prepared based on the results of flow cytometry in Experimental Example 8. [Figure 26] 1 is a graph showing the change in tumor volume over time in a study using a tumor-bearing mouse model transplanted with HepG2 cells in Experimental Example 9. [Figure 27] 1 is a graph showing the change in tumor volume over time in a study using a cancer-bearing mouse model transplanted with Li-7 cells in Experimental Example 9. [Figure 28] 13 is a graph showing the change in tumor volume over time in a study of Experimental Example 9 using a tumor-bearing mouse model transplanted with QKO PHCC cells expressing mouse Rb1 in a tetracycline-inducible manner. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] [Gene and protein names] In this specification, human genes and human proteins are represented by capital letters. Mouse genes are represented by capital letters for the first letter and lowercase letters thereafter. Mouse proteins are represented by capital letters. However, in some cases, human genes and mouse genes may be referred to without a strict distinction. In some cases, human proteins and mouse proteins may be referred to without a strict distinction.

[0009] [Pharmaceutical composition or kit] In one embodiment, the present invention provides a pharmaceutical composition for treating RB1-positive cancer, comprising a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor as active ingredients.

[0010] The pharmaceutical composition may be a pharmaceutical composition containing a mixture of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor, or a pharmaceutical composition containing a mixture of a CDK4 and 6 inhibitor and an AKT inhibitor.

[0011] In one embodiment, the CDK4 and 6 inhibitors and the NF-κB signaling pathway inhibitor or AKT inhibitor may be contained in separate containers rather than being mixed together to form a therapeutic kit, in which these drugs are administered in combination but not mixed together.

[0012] The therapeutic kit may include a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor. Alternatively, the therapeutic kit may include a combination of a CDK4 and 6 inhibitor and an AKT inhibitor.

[0013] As described later in the Examples, the inventors have demonstrated that RB1-positive cancer cells can be effectively killed in vitro and in vivo by combining CDK4 and 6 inhibitors with NF-κB signaling pathway inhibitors or AKT inhibitors.

[0014] FIG. 1 is a schematic diagram illustrating the action of CDK4 and 6 inhibitors on RB1. RB1 is dephosphorylated immediately after mitosis. Activated CDK4 and 6 monophosphorylate RB1. Once RB1 is monophosphorylated, the CDK2 complex achieves complete phosphorylation of RB1. Inhibition of the activity of CDK4 and 6 inhibits the monophosphorylation of RB1. As a result, RB1 is maintained in an unphosphorylated state for a long period of time. As a result, not only cell cycle arrest but also senescence, apoptosis, enhanced immunogenicity, etc. are induced.

[0015] RB1 positive cancer means a cancer in which the cancer cells that constitute the tumor express RB1. The RB1 expressed by RB1 positive cancer may have a mutation, but it is preferable that the above-mentioned wild-type RB1 function is maintained, and it is preferable that the RB1 is wild-type. Specific examples of RB1 positive cancer include hepatocellular carcinoma, breast cancer, lung cancer, and colon cancer.

[0016] The accession number of the human RB1 cDNA is NM_000321.3. The accession number of the human RB1 protein is NP_000312.2. The accession number of the mouse Rb1 cDNA is NM_009029.2. The accession number of the mouse RB1 protein is NP_033055.2.

[0017] In the pharmaceutical composition of this embodiment, the CDK4 and 6 inhibitor may be a drug that inhibits the activity of a complex consisting of CDK4 and 6 and cyclin D. The CDK4 and 6 inhibitor may be a low molecular weight compound or an inhibitory nucleic acid against CDK4, CDK6 or cyclin D. Examples of the inhibitory nucleic acid include shRNA and siRNA.

[0018] More specific examples of CDK4 and 6 inhibitors include palbociclib (CAS number: 571190-30-2), ribociclib (CAS number: 1211441-98-3), abemaciclib (CAS number: 1231929-97-7), trilaciclib (CAS number: 1374743-00-6), relociclib (CAS number: 1628256-23-4), etc. These may be used alone or in combination of two or more.

[0019] Furthermore, as the NF-κB signaling pathway inhibitor, a drug that blocks the NF-κB signaling pathway can be used.

[0020] The NF-κB signaling pathway is a pathway in which IκB kinase (IKK), consisting of IKKα, IKKβ, and IKKγ (NEMO), binds to and inactivates NF-κB, phosphorylating IκB, leading to ubiquitination and degradation, and as a result, NF-κB translocates from the cytoplasm to the nucleus and activates gene transcription.

[0021] The NF-κB signaling pathway inhibitor may be, for example, an IKKβ inhibitor or an NF-κB inhibitor, which may be used alone or in combination of two or more.

[0022] The NF-κB signaling pathway inhibitor may be a low molecular weight compound or an inhibitory nucleic acid against IKKα, IKKβ, IKKγ (NEMO), IκB, NF-κB, etc. Examples of the inhibitory nucleic acid include shRNA and siRNA.

[0023] Specific IKKβ inhibitors include Bay11-7082 (CAS number: 19542-67-7), IMD-0354 (CAS number: 978-62-1), IMD-1041 (CAS number: 1073666-73-5), IMD-2560, TPCA1 (CAS number: 507475-17-4), BOT-64 (CAS number: 113760-29-5), BMS345541 (CAS number: 445430-58-0), SC-514 (CAS number: 354812-17-2), IKK-16 (CAS number: 1186195-62-9), eltiprotafib (CAS number: 251303-04-5), Bay65-1942 (HCl salt) (CAS number: 600734-06-3), etc.

[0024] Specific examples of NF-κB inhibitors include QNZ (CAS number: 545380-34-5), JSH-23 (CAS number: 749886-87-1), GYY4137 (CAS number: 106740-09-4), p-XSC (CAS number: 85539-83-9), CV3988 (CAS number: 85703-73-7), prostaglandin E2 (CAS number: 363-24-6), LY294002 (CAS number: 154447-36-6), and Wortmannin. (CAS number: 19545-26-7), mesalamine (CAS number: 89-57-6), rolipram (CAS number: 85416-75-7), gallic acid (CAS number: 149-91-7), anacardic acid (CAS number: 16611-84-0), MG-115 (CAS number: 133407-86-0), MG-132 (CAS number: 133407-82-6), lactacystin (CAS number: 133343-34-7), epoxomicin (CAS number: 134381-21-8), paclitaxel (CAS number: 134381-21-8), Examples include ruthenolide (CAS number: 20554-84-1), carfilzomib (CAS number: 868540-17-4), bortezomib (CAS number: 179324-69-7), MLN-4924 (CAS number: 905579-51-3), delanzomib (CAS number: 847499-27-8), ixazomib (CAS number: 1239908-20-3), marizomib (CAS number: 437742-34-2) and oprozomib (CAS number: 935888-69-0).

[0025] The pharmaceutical composition of this embodiment may contain a combination of a CDK4 and 6 inhibitor and an AKT inhibitor as active ingredients. The CDK4 and 6 inhibitor is the same as described above. The AKT inhibitor may be a low molecular weight compound or an inhibitory nucleic acid against AKT. Examples of inhibitory nucleic acids include shRNA and siRNA.

[0026] Examples of AKT inhibitors include Akt Inhibitor X (CAS number: 925681-41-0), ipatasertib (CAS number: 1001264-89-6), capivasertib (CAS number: 1143532-39-1), mirasertib (CAS number: 1313881-70-7), afuresertib (CAS number: 1047644-62-1), uprosertib (CAS number: 1047634-65-0), triciribine phosphate (CAS number: 61966-08-3), and MK2206 (CAS number: 1032350-13-2).

[0027] The CDK4 and 6 inhibitors, and the NF-κB signaling pathway inhibitors or AKT inhibitors may be mixed with a pharma- ceutically acceptable carrier and formulated as a pharmaceutical composition.

[0028] Alternatively, the CDK4 and 6 inhibitors, the NF-κB signaling pathway inhibitor, and the AKT inhibitor may be mixed with a pharma- ceutically acceptable carrier and each formulated separately as a pharmaceutical composition to constitute a therapeutic kit.

[0029] The pharmaceutical composition is preferably formulated into a dosage form for oral use or a dosage form for parenteral use. The pharmaceutical composition may be in a dosage form for oral use or in a dosage form for parenteral use. Examples of dosage forms for oral use include tablets, capsules, elixirs, microcapsules, etc. Examples of dosage forms for parenteral use include injections, inhalants, suppositories, patches, etc.

[0030] Examples of pharma- ceutically acceptable carriers include solvents such as sterilized water and saline; binders such as gelatin, corn starch, gum tragacanth, and gum arabic; excipients such as crystalline cellulose; and bulking agents such as alginic acid.

[0031] The pharmaceutical composition may further contain additives, such as lubricants such as magnesium stearate, sweeteners such as sucrose, lactose, saccharin, flavorings such as peppermint and scallion oil, stabilizers such as benzyl alcohol and phenol, buffers such as phosphates and sodium acetate, solubilizers such as benzyl benzoate and benzyl alcohol, antioxidants, and preservatives.

[0032] The pharmaceutical compositions can be formulated by appropriately combining the above-mentioned carriers and additives and mixing them in a unit dosage form required for generally accepted pharmaceutical practice.

[0033] Administration to a patient may be by methods known to those skilled in the art, such as intra-arterial injection, intravenous injection, subcutaneous injection, as well as intranasal, transbronchial, intramuscular, transdermal, or oral administration. The dosage varies depending on the patient's weight, age, symptoms, administration method, etc., but a person skilled in the art can appropriately select an appropriate dosage.

[0034] The dosage of CDK4 and 6 inhibitors varies depending on the patient's symptoms, etc., but in the case of oral administration, it is generally considered appropriate to administer about 75 to 400 mg, for example about 75 to 125 mg, for example about 100 to 400 mg, once a day or in several divided doses in an adult (body weight 60 kg). In the case of parenteral administration, the dosage varies depending on the patient's symptoms, target organ, administration method, etc., but in the case of systemic administration, it is generally considered appropriate to administer about 30 to 200 mg, for example about 30 to 60 mg, for example about 50 to 200 mg, once a day in an adult (body weight 60 kg), once about 1 to 10 days. In the case of local administration, it is generally considered appropriate to administer about 7.5 to 40 mg, for example about 7.5 to 12.5 mg, for example about 10 to 40 mg, once a day in an adult (body weight 60 kg).

[0035] The dosage of the NF-κB signaling pathway inhibitor varies depending on the patient's symptoms, etc., but in the case of oral administration, it is generally considered appropriate to administer about 50 to 900 mg, for example about 300 to 900 mg, for example about 2 to 5 mg, once a day or in several divided doses to an adult (body weight 60 kg). In the case of parenteral administration, the dosage varies depending on the patient's symptoms, target organ, administration method, etc., but in the case of systemic administration, it is generally considered appropriate to administer about 2 to 200 mg, for example about 2 to 5 mg, for example about 50 to 200 mg, once a day to an adult (body weight 60 kg), once about 1 to 10 days. In the case of local administration, it is generally considered appropriate to administer about 2 to 100 mg, for example about 2 to 50 mg, for example about 10 to 100 mg, once a day to an adult (body weight 60 kg).

[0036] The dosage of the AKT inhibitor varies depending on the patient's symptoms, etc., but in the case of oral administration, it is generally considered appropriate to administer about 200 to 600 mg, for example about 200 to 400 mg, for example about 300 to 600 mg, once a day or in several divided doses to an adult (body weight 60 kg). In the case of parenteral administration, the dosage varies depending on the patient's symptoms, target organ, administration method, etc., but in the case of systemic administration, it is generally considered appropriate to administer about 100 to 800 mg, for example about 100 to 500 mg, for example about 400 to 800 mg, once a day to an adult (body weight 60 kg), once every 1 to 10 days. In the case of local administration, it is generally considered appropriate to administer about 10 to 100 mg, for example about 10 to 25 mg, for example about 30 to 100 mg, once a day to an adult (body weight 60 kg).

[0037] [Method for testing efficacy of administration to cancer patients] In one embodiment, the present invention provides a method for testing the effectiveness of administering a combination of a CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor to a cancer patient, comprising a step of examining whether cancer cells derived from a cancer patient are RB1 positive, wherein the RB1 positivity of the cancer cells indicates that administration of the combination is effective in treating the cancer patient.

[0038] As described later in the Examples, it has been revealed that when cancer cells are RB1 positive, the cancer cells can be effectively killed by administering a combination of CDK4 and 6 inhibitors and an NF-κB signaling pathway inhibitor or an AKT inhibitor.

[0039] Cancer cells being RB1 positive means that the cancer cells express RB1. The RB1 expressed by the cancer cells may have a mutation, but preferably maintains the above-mentioned wild-type RB1 function, and is preferably wild-type RB1.

[0040] Whether or not a cancer cell is RB1 positive can be determined, for example, by PCR amplification of the RB1 gene locus on the genomic DNA of the cancer cell, PCR amplification of the cDNA of the RB1 gene, detection of the mRNA of the RB1 gene by microarray, ELISA of the RB1 protein, Western blotting, immunochemical staining, etc. The PCR amplification product may be sequenced to analyze whether or not a mutation is present in the RB1 gene.

[0041] [Kit for testing the efficacy of administering the combination to a cancer patient] In one embodiment, the present invention provides a kit for testing the effectiveness of administration of a combination of a CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor to a cancer patient, the kit comprising a primer set for amplifying genomic DNA of the RB1 gene, a probe for genomic DNA of the RB1 gene, a primer set for amplifying cDNA of the RB1 gene, a probe for mRNA of the RB1 gene, or a specific binding substance for RB1 protein, the kit being used to test whether cancer cells derived from a cancer patient are RB1 positive, wherein the fact that the cancer cells are RB1 positive indicates that administration of the combination of the CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor is effective in treating the cancer patient.

[0042] The kit of this embodiment can be suitably used for carrying out the above-mentioned method of testing the effectiveness of administering a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor to a cancer patient.

[0043] (Primer set for genomic DNA amplification) The kit of this embodiment may contain a primer set for amplifying genomic DNA of the RB1 gene. The base sequences of the primer set are not particularly limited as long as they can amplify the RB1 gene on the genome.

[0044] When the genomic DNA of cancer cells derived from a cancer patient is amplified with a primer set for amplifying the genomic DNA of the RB1 gene, amplification of the RB1 gene is observed if the cancer cells retain the RB1 gene on their genomic DNA.

[0045] If cancer cells derived from a cancer patient retain the RB1 gene, it can be determined that administering a combination of CDK4 and 6 inhibitors and an NF-κB signaling pathway inhibitor or an AKT inhibitor to the cancer patient would be effective.

[0046] (Probe for genomic DNA) The kit of this embodiment may contain a probe for the genomic DNA of the RB1 gene. The base sequence of the probe is not particularly limited as long as it can detect the RB1 gene on the genome. The probe may constitute a nucleic acid array.

[0047] When a probe for the genomic DNA of the RB1 gene is hybridized to the genomic DNA of a cancer cell derived from a cancer patient, if the cancer cell has the RB1 gene on its genomic DNA, the probe will hybridize and the presence of the RB1 gene can be detected.

[0048] If cancer cells derived from a cancer patient retain the RB1 gene, it can be determined that administering a combination of CDK4 and 6 inhibitors and an NF-κB signaling pathway inhibitor or an AKT inhibitor to the cancer patient would be effective.

[0049] (Primer set for cDNA amplification) The kit of this embodiment may contain a primer set for amplifying cDNA of RB1 gene. The base sequence of the primer set is not particularly limited as long as it can amplify cDNA of RB1 gene.

[0050] When RNA is extracted from cancer cells derived from a cancer patient and amplified by RT-PCR using a primer set for amplifying cDNA of the RB1 gene, amplification of cDNA of the RB1 gene is observed if the cancer cells express mRNA of the RB1 gene.

[0051] If cancer cells derived from a cancer patient express mRNA of the RB1 gene, it can be determined that administering a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor to the cancer patient would be effective.

[0052] (Probe for mRNA) The kit of this embodiment may contain a probe for the mRNA of the RB1 gene. The base sequence of the probe is not particularly limited as long as it can detect the mRNA of the RB1 gene. The probe may constitute a nucleic acid array.

[0053] When RNA is extracted from cancer cells derived from a cancer patient and a probe for the mRNA of the RB1 gene is hybridized, if the cancer cells express the mRNA of the RB1 gene, the probe will hybridize and the presence of the mRNA of the RB1 gene can be detected.

[0054] If cancer cells derived from a cancer patient express mRNA of the RB1 gene, it can be determined that administering a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor to the cancer patient would be effective.

[0055] (specific binding substance) The kit of this embodiment may contain a substance that specifically binds to RB1 protein. Examples of specific binding substances include antibodies, antibody fragments, aptamers, etc. Examples of antibody fragments include F(ab')2, Fab', Fab, Fv, scFv, etc. The specific binding substance is not particularly limited as long as it can detect RB1 protein. The specific binding substance may be bound to a solid phase to constitute, for example, a flow strip, an array, etc.

[0056] The presence of RB1 protein can be detected by extracting proteins from cancer cells derived from a cancer patient and performing ELISA or Western blotting using a substance that specifically binds to RB1 protein. Alternatively, the presence of RB1 protein can be detected by subjecting a section of cancer tissue derived from a cancer patient to immunochemical staining using a substance that specifically binds to RB1 protein.

[0057] If cancer cells derived from a cancer patient express RB1 protein, it can be determined that administering a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor to the cancer patient would be effective.

[0058] [Other embodiments] In one embodiment, the present invention provides a method for treating cancer, comprising the steps of: examining whether cancer cells derived from a patient are RB1 positive; and, if the cancer cells are RB1 positive, administering to the patient a combination of a CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor.

[0059] In one embodiment, the invention provides the use of a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor for the treatment of RB1 positive cancer.

[0060] In one embodiment, the present invention provides the use of a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor for the manufacture of a pharmaceutical composition or treatment kit for treating RB1-positive cancer. EXAMPLES

[0061] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples. In the following examples, experiments using mice were performed according to a protocol (AP-153426) approved by the Animal Experiment Committee of Kanazawa University.

[0062] [Experimental Example 1] (Inactivation of the RB pathway induced the development of hepatocellular carcinoma) The RB family consists of RB1, RB Transcriptional Corepressor Like 1 (RBL1), and RB Transcriptional Corepressor Like 2 (RBL2).

[0063] In this experimental example, mice lacking the RBL1 gene and capable of conditionally knocking out the Rb1 and Rbl2 genes (hereinafter sometimes referred to as "TKO mice") were used, which further lacked the Tumor Protein P53 (Trp53) gene (hereinafter sometimes referred to as "QKO mice").

[0064] As shown in Figure 2(a), Rb1 lox / lox ;Rbl1 - / - ;Rbl2 lox / lox ;Trp53 - / - A PiggyBac transposon vector construct (pCMV-Puro-Cre-IRES2-GFP) carrying genes encoding Cre recombinase, green fluorescent protein (GFP), and puromycin resistance protein (Puro) in tandem, and an expression vector encoding the transposase (pCMV-hyPBase) were injected into the tail vein of (QKO) mice by hydrodynamic injection.

[0065] As a result, GFP fluorescence was observed in the liver 3 days after injection, and tumor formation was typically observed in the liver 2.5 months after injection, as shown in Figure 2(b). In Figure 2(b), the arrow indicates the tumor.

[0066] Primary hepatocellular carcinoma cells (hereafter referred to as "QKO PHCC") obtained from the tumor showed high expression of Ki67 and alpha-fetoprotein (AFP), which are characteristic of hepatocellular carcinoma. These results demonstrated that inactivation of the RB pathway induces the development of hepatocellular carcinoma.

[0067] [Experimental Example 2] (CDK4 / 6 inhibitors are not optimal) RB7LP is a mutant of RB1 that is not phosphorylated. RB7LP lacks the N-terminal domain of RB1, but retains all of pockets A, B, and C, and is therefore capable of binding to proteins with E2F and LxCxE motifs. However, seven serine residues known to be phosphorylated have been replaced with amino acids that are not phosphorylated. The amino acid sequence of RB7LP is shown in SEQ ID NO:1.

[0068] Therefore, RB7LP can mimic the RB1-dependent action of CDK4 / 6 inhibitors. Therefore, we expressed RB7LP in hepatocellular carcinoma cells and examined the induction of apoptosis.

[0069] Specifically, a tetracycline-inducible RB7LP expression vector (pTRE3G-puro-RB7LP-GFP) was introduced into the human hepatoma cell line HepG2. These cells (hereafter referred to as "HepG2-pTRE3G-puro-RB7LP-GFP cells") express RB7LP upon the addition of doxycycline to the medium.

[0070] Next, HepG2-pTRE3G-puro-RB7LP-GFP cells were incubated for 3 days with 1 μg / mL doxycycline in the medium, and for comparison, cells incubated in the same manner without doxycycline were used.

[0071] Next, annexin V-positive cells in each cell line were stained using the eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific), and dead cells were stained with propidium iodide (PI).

[0072] Next, each cell was analyzed using FACS Canto II (BD Biosciences). Cells with high Annexin V fluorescence and low PI fluorescence were in the early stage of apoptosis, while cells with high Annexin V and PI fluorescence were in the late stage of apoptosis.

[0073] Figure 3(a) is a graph showing the results of flow cytometry. In Figure 3(a), "DOX -" indicates the results in the absence of doxycycline, and "DOX +" indicates the results with the addition of doxycycline. The horizontal axis indicates the fluorescence intensity of annexin V, and the vertical axis indicates the fluorescence intensity of PI.

[0074] Figure 3(b) is a graph created based on the results of Figure 3(a). In Figure 3(b), the percentage of apoptotic cells is the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive). In Figure 3(b), "DOX -" indicates the results in the absence of doxycycline, and "DOX +" indicates the results with the addition of doxycycline. Additionally, "***" indicates that there is a significant difference at P<0.001 as a result of unpaired two-tailed Student's t-test.

[0075] As a result, it was revealed that induction of apoptosis by induction of RB7LP expression was insufficient, indicating that administration of CDK4 / 6 inhibitors to cancer cells was insufficient to induce apoptosis.

[0076] [Experimental Example 3] (Screening of compounds that enhance the effect of RB7LP) We screened a compound library for compounds that specifically kill HepG2-pTRE3G-puro-RB7LP-GFP cells in the presence of doxycycline.

[0077] As a compound library, a commercially available library containing 80 types of kinase inhibitors (product name "SCREEN-WELL Kinase Inhibitor Library", model number "BML-2832", Enzo Life Sciences) was used.

[0078] HepG2-pTRE3G-puro-RB7LP-GFP cells were cultured for 3 days in the presence or absence of 1 μg / mL doxycycline. Then, each cell was seeded at 20,000 cells / well in a 96-well plate, exposed to each compound at a final concentration of 1 μM in the presence or absence of 1 μg / mL doxycycline, and incubated for 24 hours. Then, the viability of each cell was measured using a commercially available kit (product name "Cell count reagent SF", Nacalai Tesque).

[0079] Figure 4 is a graph showing the results of the screening. The vertical axis of the graph shows the ratio shown in the following formula (F1). In the following formula (F1), "DOX(+) cells" show cells exposed to a compound in the presence of doxycycline, and "DOX(-) cells" show cells exposed to a compound in the absence of doxycycline. Percentage = viability of DOX(-) cells / viability of DOX(+) cells … (F1)

[0080] The horizontal axis indicates the compound number. The higher the value on the vertical axis, the more cytotoxicity specific to DOX(+) cells. As a result, it was revealed that the IKKβ inhibitor Bay11-7082 (CAS number: 19542-67-7) has cytotoxicity specific to DOX(+) cells. In other words, it was revealed that Bay11-7082 enhances the cytotoxicity of HepG2 cells in which RB7LP expression was induced.

[0081] [Experimental Example 4] (Examination of RB7LP expression and the effect of IKKβ inhibitors) We investigated the cytotoxicity of RB7LP by induction of expression and addition of IKKβ inhibitors in HepG2 cells and primary hepatocellular carcinoma cells (QKO PHCC). We used Bay11-7082, IMD-0354 (CAS number: 978-62-1), and shRNA against IKKβ as IKKβ inhibitors.

[0082] <Study using Bay11-7082> HepG2-pTRE3G-puro-RB7LP-GFP cells were cultured for 3 days in the presence or absence of 1 μg / mL doxycycline. Then, each cell was seeded on a 6-well plate and exposed to Bay11-7082 at a final concentration of 0, 5, 10, 15, 20, or 25 μM in the presence or absence of 1 μg / mL doxycycline, and incubated for 24 hours. The viability of each cell was then measured using a commercially available kit (product name: Cell count reagent SF, Nacalai Tesque).

[0083] 5 is a graph showing the survival rate of each type of cell. As a result, it was revealed that 10 to 20 μM of Bay11-7082 exhibited the most synergistic effect on the induction of RB7LP expression.

[0084] Next, for HepG2-pTRE3G-puro-RB7LP-GFP cells exposed to 15 μM Bay11-7082 for 24 hours, annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. In addition, dead cells were stained with propidium iodide (PI).

[0085] Next, flow cytometry analysis was performed to measure the percentage of cells undergoing apoptosis. Figure 6 is a graph based on the results of flow cytometry. In Figure 6, the percentage of cells undergoing apoptosis was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0086] In FIG. 6, "DOX -" indicates the results in the absence of doxycycline, and "DOX +" indicates the results with the addition of doxycycline. "BAY -" indicates the results in the absence of Bay11-7082, and "BAY +" indicates the results in the presence of Bay11-7082 at a final concentration of 15 μM. "Z-VAD -" indicates the results in the absence of Z-VAD-FMK (catalog number "3188-v", Peptide Institute, Inc.), a caspase inhibitor, and "Z-VAD +" indicates the results in the presence of Z-VAD-FMK at a final concentration of 20 μM. "*" and "****" indicate significant differences at P<0.05 and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post hoc test.

[0087] The results showed that more than 80% of HepG2-pTRE3G-puro-RB7LP-GFP cells exposed to 15 μM Bay11-7082 in the presence of doxycycline underwent apoptosis, which was significantly suppressed by the addition of Z-VAD-FMK.

[0088] This result further supports that Bay11-7082 significantly enhances the induction of apoptosis in HepG2 cells in which RB7LP expression was induced.

[0089] <Study using IMD-0354> Next, a similar study was carried out using the IKKβ inhibitor IMD-0354 (CAS number: 978-62-1) instead of Bay11-7082.

[0090] HepG2-pTRE3G-puro-RB7LP-GFP cells were cultured for 3 days in the presence or absence of 1 μg / mL doxycycline, then seeded onto 6-well plates and exposed to IMD-0354 at a final concentration of 15 μM in the presence or absence of 1 μg / mL doxycycline and incubated for 24 hours.

[0091] Next, Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Then, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0092] Figure 7 is a graph prepared based on the results of flow cytometry. In Figure 7, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0093] In Figure 7, "DOX -" indicates the results in the absence of doxycycline, and "DOX +" indicates the results with the addition of doxycycline. "IMD -" indicates the results in the absence of IMD-0354, and "IMD +" indicates the results in the presence of IMD-0354 at a final concentration of 15 μM. "**" and "****" indicate significant differences at P<0.01 and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0094] As a result, it was revealed that IMD-0354 significantly enhanced the induction of apoptosis in HepG2-pTRE3G-puro-RB7LP-GFP cells in which RB7LP expression was induced in the presence of doxycycline, indicating that IMD-0354 also exhibits an effect similar to that of Bay11-7082.

[0095] <Study using shRNA against IKKβ> Next, instead of adding an IKKβ inhibitor, we performed knockdown of IKKβ to examine whether induction of apoptosis in HepG2-pTRE3G-puro-RB7LP-GFP cells was enhanced.

[0096] As shRNA against IKKβ, commercially available shRNA expression vectors (catalog numbers "#SHCLNG-NM_001556", "TRCN0000018917", "TRCN0000018915", "TRCN0000018916", and "TRCN0000018918") in which the puromycin resistance gene had been replaced with a blastidine resistance gene were used.

[0097] We transfected four types of shRNAs into HepG2-pTRE3G-puro-RB7LP-GFP cells and confirmed the expression of IKKβ by Western blotting. We confirmed that IKKβ could be knocked down using all of the shRNAs. Therefore, we used one of these shRNAs in the next experiment.

[0098] HepG2-pTRE3G-puro-RB7LP-GFP cells transfected with or without an expression vector for shRNA against IKKβ were cultured in the presence or absence of 1 μg / mL doxycycline for 3 days, then seeded onto 6-well plates and incubated in the presence or absence of 1 μg / mL doxycycline for an additional 24 hours.

[0099] Next, Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Then, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0100] Figure 8 is a graph prepared based on the results of flow cytometry. In Figure 8, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0101] In FIG. 8, "DOX -" indicates the results in the absence of doxycycline, and "DOX +" indicates the results with the addition of doxycycline. "shRNA -" indicates the results for cells in which shRNA against IKKβ was not introduced, and "shRNA +" indicates the results for cells in which shRNA against IKKβ was introduced. "****" indicates that there is a significant difference at P<0.0001 as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0102] The results showed that knockdown of IKKβ significantly enhanced the induction of apoptosis in HepG2-pTRE3G-puro-RB7LP-GFP cells induced with RB7LP expression in the presence of doxycycline, further supporting that functional inhibition of IKKβ significantly enhanced the induction of apoptosis in HepG2 cells induced with RB7LP expression.

[0103] 《Study using primary hepatocellular carcinoma cells (QKO PHCC)》 Instead of HepG2-pTRE3G-puro-RB7LP-GFP cells, an investigation was carried out using the QKO PHCCs obtained in Experimental Example 1.

[0104] We generated cells by introducing an RB7LP expression vector (plenti6.3-RB7LP) into QKO PHCC (hereinafter referred to as "RB7LP(+) QKO PHCC cells") and cells by introducing a LacZ expression vector (plenti6.3 / V5-LacZ) into QKO PHCC (hereinafter referred to as "RB7LP(-) QKO PHCC cells").

[0105] Subsequently, RB7LP(+)QKO PHCC cells and RB7LP(-)QKO PHCC cells were exposed to Bay11-7082 at a final concentration of 15 μM and incubated for 24 hours.

[0106] Next, Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Then, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0107] Figure 9 is a graph prepared based on the results of flow cytometry. In Figure 9, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0108] In FIG. 9, "RB7LP -" indicates the results for RB7LP(-)QKO PHCC cells, and "RB7LP +" indicates the results for RB7LP(+)QKO PHCC cells. "BAY -" indicates the results in the absence of Bay11-7082, and "BAY +" indicates the results in the presence of Bay11-7082 at a final concentration of 15 μM. "*" and "****" indicate significant differences at P<0.05 and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0109] The results showed that Bay11-7082 significantly enhanced the induction of apoptosis in RB7LP-expressing QKO PHCC cells, a result similar to that observed in HepG2 cells.

[0110] [Experimental Example 5] (Examination of the combined effects of CDK4 and 6 inhibitors and IKKβ inhibitors) Various cancer cell lines were incubated in the presence of CDK4 and 6 inhibitors and IKKβ inhibitors, and then Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Flow cytometry analysis was then performed to measure the proportion of cells that had undergone apoptosis.

[0111] The cancer cell lines used were human liver cancer cell lines Huh7, Li-7, and HepG2, human lung cancer cell line H1975, human breast cancer cell lines HCC1143 and T47D, and human colon cancer cell lines HCT-116 and DLD-1. All of these cells are known to be RB1 positive.

[0112] Palbociclib (CAS number: 571190-30-2), ribociclib (CAS number: 1211441-98-3), or abemaciclib (CAS number: 1231929-97-7) were used as CDK4 and 6 inhibitors, and Bay11-7082 was used as an IKKβ inhibitor.

[0113] Combination of palbociclib and Bay11-7082 Huh7 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Bay11-7082 at a final concentration of 10 μM. Li-7 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Bay11-7082 at a final concentration of 15 μM. H1975 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Bay11-7082 at a final concentration of 10 μM. HCC1143 cells were incubated for 4 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Bay11-7082 at a final concentration of 10 μM. T47D cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Bay11-7082 at a final concentration of 10 μM. HCT-116 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 8 μM and Bay11-7082 at a final concentration of 15 μM. DLD-1 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 8 μM and Bay11-7082 at a final concentration of 15 μM.

[0114] Figures 10 to 16 are graphs prepared based on the results of flow cytometry. In Figures 10 to 16, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0115] Figure 10 shows the results for Huh7 cells, Figure 11 shows the results for Li-7 cells, Figure 12 shows the results for H1975 cells, Figure 13 shows the results for HCC1143 cells, Figure 14 shows the results for T47D cells, Figure 15 shows the results for HCT-116 cells, and Figure 16 shows the results for DLD-1 cells.

[0116] In Figures 10 to 16, "Palbo. -" indicates the results in the absence of palbociclib, and "Palbo. +" indicates the results in the presence of palbociclib. "BAY -" indicates the results in the absence of Bay11-7082, and "BAY +" indicates the results in the presence of Bay11-7082. "ns", "*", "**" and "****" indicate no significant difference, significant difference at P<0.05, P<0.01 and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0117] As a result, it was revealed that the induction of apoptosis was significantly enhanced by the combined use of CDK4 and 6 inhibitors and IKKβ inhibitors in all cancer cell lines. This result indicates that the combined use of CDK4 and 6 inhibitors and IKKβ inhibitors is effective not only in hepatocellular carcinoma but also in lung cancer, breast cancer, and colon cancer.

[0118] Combination of ribociclib and Bay11-7082 We investigated the effect of ribociclib as an inhibitor of CDK4 and 6. HepG2 cells were incubated for 24 hours in the presence or absence of ribociclib (final concentration 8 μM) and Bay11-7082 (final concentration 15 μM).

[0119] Next, Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Then, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0120] Figure 17 is a graph prepared based on the results of flow cytometry. In Figure 17, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0121] In FIG. 17, "Ribo. -" indicates the results in the absence of ribociclib, and "Ribo. +" indicates the results in the presence of ribociclib. "BAY -" indicates the results in the absence of Bay11-7082, and "BAY +" indicates the results in the presence of Bay11-7082. "ns" and "****" indicate no significant difference and a significant difference at P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0122] As a result, it was revealed that even when ribociclib was used as a CDK4 and 6 inhibitor, the induction of apoptosis was significantly enhanced by combination with an IKKβ inhibitor.

[0123] Combination of Abemaciclib and Bay11-7082 Abemaciclib was used as an inhibitor of CDK4 and 6. HepG2 cells were incubated for 24 hours in the presence or absence of abemaciclib (final concentration 6 μM) and Bay11-7082 (final concentration 10 μM).

[0124] Next, Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Then, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0125] Figure 18 is a graph prepared based on the results of flow cytometry. In Figure 18, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0126] In FIG. 18, "Abema. -" indicates the results in the absence of abemaciclib, and "Abema. +" indicates the results in the presence of abemaciclib. "BAY -" indicates the results in the absence of Bay11-7082, and "BAY +" indicates the results in the presence of Bay11-7082. "****" indicates that there is a significant difference at P<0.0001 as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0127] As a result, it was revealed that even when abemaciclib was used as a CDK4 and 6 inhibitor, the induction of apoptosis was significantly enhanced by combination with an IKKβ inhibitor.

[0128] [Experimental Example 6] (Examination of RB7LP expression and the effect of NF-κB inhibitors) Instead of the IKKβ inhibitor, we used an NF-κB inhibitor to examine the induction of RB7LP expression and the induction of apoptosis by the addition of an NF-κB inhibitor. QNZ (CAS number: 545380-34-5) was used as the NF-κB inhibitor.

[0129] HepG2-pTRE3G-puro-RB7LP-GFP cells were cultured for 3 days in the presence or absence of 1 μg / mL doxycycline, then seeded onto 6-well plates and exposed to 50 nM QNZ in the presence or absence of 1 μg / mL doxycycline and incubated for 24 hours.

[0130] Next, Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Then, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0131] Figure 19 is a graph prepared based on the results of flow cytometry. In Figure 19, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0132] In Figure 19, "DOX -" indicates the results in the absence of doxycycline, and "DOX +" indicates the results with the addition of doxycycline. "QNZ -" indicates the results in the absence of QNZ, and "QNZ +" indicates the results in the presence of QNZ. "**" and "****" indicate significant differences at P<0.01 and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0133] As a result, it was revealed that QNZ significantly enhanced the induction of apoptosis in HepG2-pTRE3G-puro-RB7LP-GFP cells in which RB7LP expression was induced in the presence of doxycycline, indicating that the NF-κB inhibitor has a similar effect to the IKKβ inhibitor.

[0134] [Experimental Example 7] (Examination of the combined effects of CDK4 and 6 inhibitors and AKT inhibitors) An investigation was carried out using an AKT inhibitor instead of an IKKβ inhibitor. After incubating various cancer cell lines in the presence of CDK4 and 6 inhibitors and an AKT inhibitor, Annexin V-positive cells were stained using the eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. In addition, dead cells were stained with propidium iodide (PI). Subsequently, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0135] The cancer cell lines used were the human liver cancer cell line HepG2, the human colon cancer cell lines SW480, HCT-116, and DLD-1, and the human lung cancer cell line A549.

[0136] Palbociclib (CAS number: 571190-30-2) was used as a CDK4 and 6 inhibitor, and Akt Inhibitor X (CAS number: 925681-41-0) was used as an AKT inhibitor.

[0137] HepG2 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Akt Inhibitor X at a final concentration of 25 μM. SW480 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Akt Inhibitor X at a final concentration of 20 μM. HCT-116 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Akt Inhibitor X at a final concentration of 20 μM. DLD-1 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Akt Inhibitor X at a final concentration of 20 μM. A549 cells were incubated for 24 hours in the presence or absence of palbociclib at a final concentration of 10 μM and Akt Inhibitor X at a final concentration of 20 μM.

[0138] 20 to 24 are graphs prepared based on the results of flow cytometry. In Fig. 20 to 24, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0139] FIG. 20 shows the results for HepG2 cells, FIG. 21 shows the results for SW480 cells, FIG. 22 shows the results for HCT-116 cells, FIG. 23 shows the results for DLD-1 cells, and FIG. 24 shows the results for A549 cells.

[0140] In Figures 20 to 24, "Palbo. -" indicates the results in the absence of palbociclib, and "Palbo. +" indicates the results in the presence of palbociclib. "CAS -" indicates the results in the absence of Akt Inhibitor X, and "CAS +" indicates the results in the presence of Akt Inhibitor X. "*", "***", and "****" indicate that there is a significant difference at P<0.05, P<0.001, and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0141] As a result, it was revealed that the induction of apoptosis was significantly enhanced by the combined use of CDK4 and 6 inhibitors and AKT inhibitors in all cancer cell lines. This result indicates that the combined use of CDK4 and 6 inhibitors and AKT inhibitors is effective not only in hepatocellular carcinoma but also in colon cancer and lung cancer.

[0142] [Experimental Example 8] (Investigation of the effect of RB1 expression on the combined effects of CDK4 and 6 inhibitors and IKKβ inhibitors) The effect of RB1 expression on the combined effect of CDK4 and 6 inhibitors and an IKKβ inhibitor was examined.

[0143] First, we transfected QKO PHCC cells with a tetracycline-inducible Rb1 expression vector, and these cells (hereafter referred to as "QKO-PHCC-pTRE3G-blast-mouse Rb1-mcherry cells") expressed Rb1 upon the addition of doxycycline to the medium.

[0144] Next, QKO-PHCC-pTRE3G-blast-mouse Rb1-mcherry cells were cultured for 3 days in the presence or absence of 1 μg / mL doxycycline. Then, each cell was seeded on a 6-well plate and incubated for 24 hours in the presence or absence of 1 μg / mL doxycycline, in the presence or absence of palbociclib at a final concentration of 10 μM, and in the presence or absence of Bay11-7082 at a final concentration of 15 μM.

[0145] Next, Annexin V-positive cells were stained using eBioscience Annexin V-FITC Apoptosis Detection Kit (Thermo Fisher Scientific) in the same manner as in Experimental Example 2. Dead cells were stained with propidium iodide (PI). Then, flow cytometry analysis was performed to measure the proportion of cells that had undergone apoptosis.

[0146] Figure 25 is a graph prepared based on the results of flow cytometry. In Figure 25, the percentage of apoptotic cells was calculated as the sum of the percentage of cells in the early stage of apoptosis (Annexin V positive, PI negative) and the percentage of cells in the late stage of apoptosis (Annexin V positive, PI positive).

[0147] In FIG. 25, "DOX -" indicates the results in the absence of doxycycline, and "DOX +" indicates the results with the addition of doxycycline. "Palbo. -" indicates the results in the absence of palbociclib, and "Palbo. +" indicates the results in the presence of palbociclib. "BAY -" indicates the results in the absence of Bay11-7082, and "BAY +" indicates the results in the presence of Bay11-7082. "**" and "****" indicate that there is a significant difference at P<0.01 and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0148] As a result, in the absence of Rb1, the apoptosis-inducing effect of the combination of palbociclib and Bay11-7082 was only slightly observed. In contrast, in the presence of Rb1, the induction of apoptosis by the combination of palbociclib and Bay11-7082 was significantly enhanced. This result indicates that the presence or absence of RB1 in cancer cells is a marker that indicates the effectiveness of the combination of CDK4 and 6 inhibitors and IKKβ inhibitors.

[0149] [Experimental Example 9] (In vivo study of the combined effects of CDK4 / 6 inhibitors and IKKβ inhibitors) We administered CDK4 / 6 inhibitors and IKKβ inhibitors to tumor-bearing mouse models and measured the changes in tumor volume over time.

[0150] The tumor-bearing mouse models used were: a tumor-bearing mouse model transplanted with HepG2 cells, a tumor-bearing mouse model transplanted with Li-7 cells, and a tumor-bearing mouse model transplanted with QKO PHCC cells (QKO-PHCC-pTRE3G-blast-mouse Rb1-mcherry cells) that express mouse Rb1 in a tetracycline-inducible manner.

[0151] Palbociclib (CAS number: 571190-30-2) was used as a CDK4 and 6 inhibitor, and Bay11-7082 was used as an IKKβ inhibitor.

[0152] <Study using a tumor-bearing mouse model transplanted with HepG2 cells> HepG2 cells 1 x 10 6 The cells were then subcutaneously transplanted into the back of KSN / slc mice (6 weeks old, male) together with Matrigel (catalog number "354234", Corning Inc.) to create a tumor-bearing mouse model. After about 4 weeks, the tumor size increased to about 200 mm 3After reaching the tumor size of 100 μg / kg, the mice in the test group were administered palbociclib and Bay11-7082. Palbociclib was administered daily by oral gavage at a dose of 80 mg / Kg. Bay11-7082 was dissolved in corn oil and administered by subcutaneous injection at a dose of 20 mg / Kg every 2 days. The control group was administered with vehicle (corn oil or sodium L-lactate). The tumor volume and body weight of each group were measured every 2 days (n=5).

[0153] Figure 26 is a graph showing the change in tumor volume over time in each group of mice, in which the vertical axis shows the rate of increase in tumor volume (%) and the horizontal axis shows the number of days after the start of drug administration.

[0154] In FIG. 26, "Palbo. -" indicates the results of mice that were not administered palbociclib, and "Palbo. +" indicates the results of mice that were administered palbociclib. "BAY -" indicates the results of mice that were not administered Bay11-7082, and "BAY +" indicates the results of mice that were administered Bay11-7082. "*", "***", and "****" indicate that there is a significant difference at P<0.05, P<0.01, and P<0.0001, respectively, as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0155] As a result, administration of palbociclib alone slightly suppressed the increase in tumor volume compared to the non-administration group. It was also revealed that the combined administration of palbociclib and Bay11-7082 almost completely suppressed the increase in tumor volume. There was also no significant difference in the body weight of the mice in each group. This result indicates that the combined use of CDK4 and 6 inhibitors and IKKβ inhibitors is also effective in vivo.

[0156] <Study using a tumor-bearing mouse model transplanted with Li-7 cells> Li-7 cells 1 x 10 6The cells were subcutaneously transplanted together with Matrigel (Corning, Catalog No. 354234) into the dorsal skin of KSN / slc mice (6 weeks old, male) to create a tumor-bearing mouse model. After about 5 weeks, the tumor size increased to about 200 mm 3 After reaching the tumor size of 100 μg / kg, the mice in the test group were administered palbociclib and Bay11-7082. Palbociclib was administered daily by oral gavage at a dose of 80 mg / Kg. Bay11-7082 was dissolved in corn oil and administered by subcutaneous injection at a dose of 20 mg / Kg every 2 days. The control group was administered with vehicle (corn oil or sodium L-lactate). The tumor volume and body weight of each group were measured every 2 days (n=5).

[0157] Figure 27 is a graph showing the change in tumor volume over time in each group of mice, in which the vertical axis shows the rate of increase in tumor volume (%) and the horizontal axis shows the number of days after the start of drug administration.

[0158] In FIG. 27, "Palbo. -" indicates the results of mice that were not administered palbociclib, and "Palbo. +" indicates the results of mice that were administered palbociclib. "BAY -" indicates the results of mice that were not administered Bay11-7082, and "BAY +" indicates the results of mice that were administered Bay11-7082. "****" indicates that there is a significant difference at P<0.0001 as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0159] As a result, administration of palbociclib alone significantly suppressed the increase in tumor volume compared to the non-administration group. It was also revealed that combined administration of palbociclib and Bay11-7082 significantly reduced tumor volume. There was also no significant difference in the body weight of the mice in each group. This result indicates that the combined use of CDK4 and 6 inhibitors and IKKβ inhibitors is effective in vivo in tumors derived from Li-7 cells.

[0160] <<Study using a tumor-bearing mouse model transplanted with QKO PHCC cells expressing mouse Rb1 in a tetracycline-inducible manner>> QKO-PHCC-pTRE3G-blast-mouse Rb1-mcherry cells 5×10 5 The tumor-bearing mice were then subcutaneously transplanted into the back of KSN / slc mice (6 weeks old, male) together with Matrigel (catalog number "354234", Corning Inc.) to create tumor-bearing mice models. 3 After reaching this threshold, mice in the test group were administered doxycycline, palbociclib, and Bay11-7082.

[0161] Doxycycline (50mg / Kg) and palbociclib (80mg / Kg) were administered daily by oral gavage. Bay11-7082 was dissolved in corn oil and administered by subcutaneous injection at a dose of 20mg / Kg every 2 days. Vehicles (0.9% NaCl, corn oil, or sodium L-lactate) were administered to the control group. Tumor volumes and body weights were measured every 2 days for each group of mice (n=5).

[0162] Figure 28 is a graph showing the change in tumor volume over time in each group of mice, in which the vertical axis shows the rate of increase in tumor volume (%) and the horizontal axis shows the number of days after the start of drug administration.

[0163] In FIG. 28, "DOX -" indicates the results of mice that were not administered doxycycline, and "DOX +" indicates the results of mice that were administered doxycycline. "Palbo. -" indicates the results of mice that were not administered palbociclib, and "Palbo. +" indicates the results of mice that were administered palbociclib. "BAY -" indicates the results of mice that were not administered Bay11-7082, and "BAY +" indicates the results of mice that were administered Bay11-7082. "****" indicates that there is a significant difference at P<0.0001 as a result of two-way ANOVA followed by Tukey's post-hoc test.

[0164] As a result, administration of palbociclib alone significantly suppressed the increase in tumor volume compared to the non-administration group. It was also revealed that combined administration of palbociclib and Bay11-7082 significantly reduced tumor volume. There was also no significant difference in the body weight of the mice in each group. This result indicates that the combined use of CDK4 and 6 inhibitors and IKKβ inhibitors is effective in vivo in tumors derived from Li-7 cells.

[0165] As a result, in the absence of Rb1, the combined administration of palbociclib and Bay11-7082 only slightly suppressed the increase in tumor volume. In contrast, in the presence of Rb1, the combined administration of palbociclib and Bay11-7082 significantly reduced tumor volume. This result further supports the idea that the presence or absence of RB1 in cancer cells is a marker for the efficacy of the combined use of CDK4 and 6 inhibitors and IKKβ inhibitors. [Industrial Applicability]

[0166] According to the present invention, a technique for effectively treating RB1-positive cancer can be provided.

Claims

1. A pharmaceutical composition for treating RB Transcriptional Corepressor 1 (RB1)-positive cancer, comprising a combination of a cyclin-dependent kinase (CDK) 4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor as active ingredients, The CDK4 and 6 inhibitor is palbociclib (CAS number: 571190-30-2), ribociclib (CAS number: 1211441-98-3) or abemaciclib (CAS number: 1231929-97-7); the NF-κB signaling pathway inhibitor is an IKKβ inhibitor or an NF-κB inhibitor; The IKKβ inhibitor is Bay11-7082 (CAS number: 19542-67-7), IMD-0354 (CAS number: 978-62-1), or an inhibitory nucleic acid against IKKβ; The NF-κB inhibitor is QNZ (CAS number: 545380-34-5), The AKT inhibitor is Akt Inhibitor X (CAS number: 925681-41-0), The pharmaceutical composition, wherein the RB1 positive cancer is hepatocellular carcinoma or lung cancer.

2. A kit for treating RB1-positive cancer, comprising an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and an inhibitor of the NF-κB signaling pathway or an inhibitor of AKT, the CDK4 and 6 inhibitor is palbociclib, ribociclib, or abemaciclib; the NF-κB signaling pathway inhibitor is an IKKβ inhibitor or an NF-κB inhibitor; the IKKβ inhibitor is Bay11-7082, IMD-0354, or an inhibitory nucleic acid against IKKβ; The NF-κB inhibitor is QNZ; the AKT inhibitor is Akt Inhibitor X, The therapeutic kit, wherein the RB1-positive cancer is hepatocellular carcinoma or lung cancer.

3. A method comprising the step of testing whether a cancer cell derived from a cancer patient is RB1 positive; 13. A method for testing the effectiveness of administering a combination of a CDK4 and 6 inhibitor and an NF-κB signaling pathway inhibitor or an AKT inhibitor to a cancer patient, wherein the cancer cells are RB1 positive, indicating that the administration of the combination is effective in treating the cancer patient, comprising: the CDK4 and 6 inhibitor is palbociclib, ribociclib, or abemaciclib; the NF-κB signaling pathway inhibitor is an IKKβ inhibitor or an NF-κB inhibitor; the IKKβ inhibitor is Bay11-7082, IMD-0354, or an inhibitory nucleic acid against IKKβ; The NF-κB inhibitor is QNZ; the AKT inhibitor is Akt Inhibitor X, The method, wherein the RB1 positive cancer is hepatocellular carcinoma or lung cancer.

4. A primer set for amplifying genomic DNA of the RB1 gene; A probe for the genomic DNA of the RB1 gene, A primer set for amplifying cDNA of the RB1 gene, A probe for the mRNA of the RB1 gene, or a specific binding substance for RB1 protein, Cancer cells derived from a cancer patient are used to test whether they are RB1 positive, A kit for testing the effectiveness of administering a combination of a CDK4 and 6 inhibitor, and an NF-κB signaling pathway inhibitor or an AKT inhibitor to a cancer patient, wherein the cancer cells being RB1 positive indicates that the administration of the combination is effective in treating the cancer patient, the CDK4 and 6 inhibitor is palbociclib, ribociclib, or abemaciclib; the NF-κB signaling pathway inhibitor is an IKKβ inhibitor or an NF-κB inhibitor; the IKKβ inhibitor is Bay11-7082, IMD-0354, or an inhibitory nucleic acid against IKKβ; The NF-κB inhibitor is QNZ; the AKT inhibitor is Akt Inhibitor X, The kit, wherein the RB1-positive cancer is hepatocellular carcinoma or lung cancer.

Citation Information

Patent Citations

  • Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor

    WO2019166928A1